1. Scrip
  2. >>Business

Canadian Biotech Takes COVID-19 Nasal Spray To Asia Via Glenmark

Eyes On Effectiveness Against Variants

 
• By Anju Ghangurde

Glenmark hopes to launch SaNOtize’s nitric oxide nasal spray for COVID-19 in India by the fourth quarter of 2021 post Phase III trials, as part of wider deal that covers other Asian markets. Can the self-administered product impact market dynamics positioned as the first line of defense against COVID-19?

partnering
SaNOtize-Glenmark Partner For COVID-19 Nasal Spray • Source: Alamy

The Vancouver, Canada-based biotech firm SaNOtize Research and Development Corporation has delivered on its intent for an India-based alliance, now sewing up an exclusive long-term deal with Glenmark Pharmaceuticals Limited to manufacture, market and distribute its novel Nitric Oxide Nasal Spray (NONS) for COVID-19.

Glenmark will commercialize NONS in India and certain other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.